Ionis Subsidiary Akcea Therapeutics Prices $125M IPO
Akcea Therapeutics Inc., a late-stage biotech being spun out of Ionis Pharmaceuticals Inc., on Thursday priced a $125 million initial public offering, under guidance from Cooley LLP....To view the full article, register now.
Already a subscriber? Click here to view full article